Danazol
NDC Package 68151-2298-0

11-digit billing NDC: 68151229800

Package Information

This product is EXCLUDED from the official NDC directory because the listing data was inactivated by the FDA.

Danazol is endometriosisDanazol capsules are indicated for the treatment of endometriosis amenable to hormonal management.Fibrocystic Breast DiseaseMost cases of symptomatic fibrocystic breast disease may be treated by simple measures (e.g., padded brassieres and analgesics).In infrequent patients, symptoms of pain and tenderness may be severe enough to warrant treatment by suppression of ovarian function. Marketed by Carilion Materials Management, this product is identified by NDC 68151-2298 and is authorized under FDA application ANDA077246.

Identification & Billing

NDC Package Code
68151-2298-0
Package Description
1 CAPSULE in 1 PACKAGE
Product Code
11-Digit Billing Format
68151229800
RxNorm Crosswalk
RxCUI: 197555 - danazol 200 MG Oral Capsule

Clinical Specifications

Proprietary Name
Danazol
Dosage Form
-
Usage Information
EndometriosisDanazol capsules are indicated for the treatment of endometriosis amenable to hormonal management.Fibrocystic Breast DiseaseMost cases of symptomatic fibrocystic breast disease may be treated by simple measures (e.g., padded brassieres and analgesics).In infrequent patients, symptoms of pain and tenderness may be severe enough to warrant treatment by suppression of ovarian function. Danazol capsules are usually effective in decreasing nodularity, pain, and tenderness. It should be stressed to the patient that this treatment is not innocuous in that it involves considerable alterations of hormone levels and that recurrence of symptoms is very common after cessation of therapy.Hereditary AngioedemaDanazol capsules are indicated for the prevention of attacks of angioedema of all types (cutaneous, abdominal, laryngeal) in males and females.

Regulatory & Marketing

Labeler Name
Carilion Materials Management
FDA Application #
ANDA077246
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
09-28-2005
Listing Expiration
12-31-2018
Exclude Flag
I
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 68151-2298-0 identifies a specific commercial package of 1 capsule in 1 package of Danazol, labeled by Carilion Materials Management. This is formulated for use and contains as the active substance.

Is this product currently listed with the FDA?

This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Carilion Materials Management on September 28, 2005. The current certification is valid through December 31, 2018.

How is this Carilion Materials Management product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 68151229800. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-4-1)
68151-2298-0
11-Digit CMS (5-4-2)
68151-2298-00

Note: The zero is added to the Package segment to maintain the 5-4-2 structure.